Contact Us
UBC Insights

Insights from
UBC's Expert Voices

Featured Updates

Featured Image
Blog
August 3, 2026 15 min read

Real-World Evidence in EU Joint Clinical Assessments: Strategic Use and Methodological Standards
With immature survival data, single-arm trials, and limited comparators common in early JCA submissions, real-world evidence is becoming a strategic necessity, not an afterthought. Learn how sponsors can plan and generate RWE that meets the methodological bar EU assessors expect.
Walid Shouman
M.Pharm, Associate Research Scientist
Featured Image
Blog
July 30, 2026 16 min read

From Approval to Access: Adopting a “One Evidence Package” Mindset for Success in the EU Joint Clinical Assessment Era
The EU Joint Clinical Assessment is driving a new approach to evidence generation, where regulatory approval and market access considerations must be addressed together. Drawing on lessons from the first completed and discontinued JCA cases, this article explores how integrated evidence planning, comparative effectiveness evidence, proactive PICO management, and strategic use of real-world evidence can help organizations navigate evolving European requirements and support successful reimbursement and patient access outcomes.
Judy Lytle
Executive Director of Evidence Development Study Solutions
Featured Image
Blog
July 27, 2026 11 min read

Navigating the AI Landscape: Expanding the Toolbox (Part 2) and Having a Little Fun Along the Way 
AI can support much more than drafting content. In Part 2 of our series, we explore practical tools that help teams organize information, improve communication, capture meeting insights, visualize complex concepts, and work more efficiently so experts can stay focused on what matters most.
Poonam Pathak
Manager, Pharmacovigilance

Posts by Date

Featured Image
Blog
August 3, 2026 15 min read

Real-World Evidence in EU Joint Clinical Assessments: Strategic Use and Methodological Standards
With immature survival data, single-arm trials, and limited comparators common in early JCA submissions, real-world evidence is becoming a strategic necessity, not an afterthought. Learn how sponsors can plan and generate RWE that meets the methodological bar EU assessors expect.
Walid Shouman
M.Pharm, Associate Research Scientist
Featured Image
Blog
July 30, 2026 16 min read

From Approval to Access: Adopting a “One Evidence Package” Mindset for Success in the EU Joint Clinical Assessment Era
The EU Joint Clinical Assessment is driving a new approach to evidence generation, where regulatory approval and market access considerations must be addressed together. Drawing on lessons from the first completed and discontinued JCA cases, this article explores how integrated evidence planning, comparative effectiveness evidence, proactive PICO management, and strategic use of real-world evidence can help organizations navigate evolving European requirements and support successful reimbursement and patient access outcomes.
Judy Lytle
Executive Director of Evidence Development Study Solutions
Featured Image
Blog
July 27, 2026 11 min read

Navigating the AI Landscape: Expanding the Toolbox (Part 2) and Having a Little Fun Along the Way 
AI can support much more than drafting content. In Part 2 of our series, we explore practical tools that help teams organize information, improve communication, capture meeting insights, visualize complex concepts, and work more efficiently so experts can stay focused on what matters most.
Poonam Pathak
Manager, Pharmacovigilance
Featured Image
Blog
July 16, 2026 7 min read

Why 95% Compliance Isn’t Enough: The Hidden Cost of That 4–5% Gap
A 95% compliance rate sounds strong, until you calculate what it means at 100,000 cases a year. Here's what's actually hiding in that gap, and the four questions every sponsor should ask before signing with a PV vendor.
Tom Coles
Director, Pharmacovigilance
Featured Image
Blog
July 14, 2026 10 min read

The Centaur Model: What the Future of Pharmacovigilance Actually Looks Like 
AI isn't replacing pharmacovigilance professionals. It's changing how they work. Learn why the centaur model, where humans direct AI rather than defer to it, is emerging as the standard for regulated safety operations.
Featured Image
Blog
July 1, 2026 8 min read

The True Cost of Cheap PV: A Framework for Evaluating Your Options
AI savings numbers are easy to put in a proposal. What's harder to find is what happens when something goes wrong. Here's a framework for pricing in the risk that vendor pitches leave out, plus four questions worth asking before you switch.
Featured Image
Blog
June 25, 2026 10 min read

Five Ways AI is Already Changing Case Processing and Where Humans are Still Needed
From triage to causality assessment, AI is changing how case processing teams work. We break down five areas where automation is making an impact, and the human expertise that still has to anchor every decision.
Dobrochna Dolicka
Safety Scientist, Global Safety Writing
Featured Image
Blog
June 19, 2026 25 min read

Novel Treatments for Mental Health and Considerations for Risk Management
Psychedelic-assisted therapies are emerging as a promising frontier for treatment-resistant mental health conditions. As the regulatory landscape evolves, robust risk management frameworks will be critical to bringing these therapies safely to patients. UBC explores the current landscape and what approval pathways may mean for sponsors.
Featured Image
Blog
June 17, 2026 7 min read

The AI vs. Automation Question Nobody in PV Is Asking Clearly
Automation and AI are often used interchangeably in PV, but they're built for different jobs. This piece breaks down where each one delivers value, and how to choose the right fit without adding unnecessary complexity.
1 2 3 … 20

Press Inquires
UBC logo white

Thank You for Connecting with UBC

.

 

What You Can Expect Next

.

  • Leverage automation to move fast
  • Always give customers a human to chat to
  • Automate customer support and close leads faster
Return to Homepage
Connect with Us on LinkedIn
UBC logo white

Get Ready to Change Your Business

.

Service Request

Bekki Bracken Brown Headshot

Bekki Bracken Brown

President & Chief Executive Officer

Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.

With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.